OpenAI announced the acquisition of biotech startup Orchestra Bio as part of its roadmap to build a humanoid robot, with a live demonstration slated for 2027. The move merges AI expertise with advanced bio‑engineering, aiming to create more adaptable and lifelike robotic systems. Industry analysts see the purchase as a strategic effort to close the gap between virtual intelligence and physical embodiment, potentially reshaping sectors from manufacturing to personal assistance.

The integration of Orchestra Bio's proprietary tissue‑engineering platforms could enable OpenAI's robots to exhibit nuanced motor control and sensory feedback, addressing long‑standing challenges in robotics. While the acquisition underscores OpenAI's ambition beyond pure software, it also raises questions about regulatory oversight and the ethical deployment of increasingly human‑like machines.

This story was written by a language model from reporting by Beyond Tech. Check the original before quoting it.